Want to see HK:2235 full AI Analyst Report?
2235 Stock Chart & Stats
HK$7.10
-HK$0.10(-1.77%)
At close: 4:00 PM EST
HK$7.10
-HK$0.10(-1.77%)
Day’s Range― - ―
52-Week RangeHK$5.70 - HK$9.17
Previous CloseN/A
Volume41.60K
Average Volume (3M)340.61K
Market Cap
HK$3.09B
Enterprise ValueHK$1.19B
Total Cash (Recent Filing)HK$1.55B
Total Debt (Recent Filing)HK$91.37M
Price to Earnings (P/E)59.0
Beta0.37
Next Earnings
Aug 28, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.11
Shares Outstanding169,175,840
10 Day Avg. Volume114,320
30 Day Avg. Volume340,611
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)1.42
Price to Sales (P/S)4.33
P/FCF Ratio-468.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$11.63Price Target Upside63.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.21
Revenue Forecast (FY)HK$893.06M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained, rapid revenue growth (101.1% in 2025) signals expanding product adoption and market share in diabetes care. Durable demand for pumps and follow-on consumables should lengthen revenue visibility, enabling scale benefits and supporting long-term investment in R&D and distribution.
Gross Margin StabilityA consistent ~53% gross margin across 2024–2025 indicates resilient unit economics and pricing power in core devices and consumables. Stable gross margin supports long-term margin sustainability as the installed base grows and recurring consumables continue to generate high-margin revenue.
Conservative Balance SheetVery low leverage (debt-to-equity ~0.05) gives the company durable financial flexibility to fund growth initiatives, weather industry cycles, and invest in commercial expansion or product development without near-term refinancing risk, supporting long-term strategic optionality.
Bears Say
Negative Free Cash FlowDespite improving operating cash flow, persistently negative free cash flow (~-6.1M in 2025) reflects ongoing investment or working capital needs. If sustained, this can constrain organic reinvestment, delay self-funded expansion, or require external financing to support growth initiatives.
Operating Profitability Not ProvenEBIT and EBITDA still slightly negative in 2025 despite revenue growth, indicating operating leverage has not fully converted scale into sustainable operating profits. The company needs to demonstrate consistent positive operating margins to validate long-term profitability economics.
Low Returns On CapitalROE of ~1.9% in 2025 remains modest given the scale-up; prior negative returns underscore a multi-year recovery. Low returns on equity suggest current capital deployment hasn’t yet yielded strong profitability, requiring improvement in margin conversion and asset efficiency to drive investor returns.
MicroTech Medical (Hangzhou) Co., Ltd. Class H News
2235 FAQ
What was MicroTech Medical (Hangzhou) Co., Ltd. Class H’s price range in the past 12 months?
MicroTech Medical (Hangzhou) Co., Ltd. Class H lowest stock price was HK$5.70 and its highest was HK$9.17 in the past 12 months.
What is MicroTech Medical (Hangzhou) Co., Ltd. Class H’s market cap?
MicroTech Medical (Hangzhou) Co., Ltd. Class H’s market cap is HK$3.09B.
When is MicroTech Medical (Hangzhou) Co., Ltd. Class H’s upcoming earnings report date?
MicroTech Medical (Hangzhou) Co., Ltd. Class H’s upcoming earnings report date is Aug 28, 2026 which is in 54 days.
How were MicroTech Medical (Hangzhou) Co., Ltd. Class H’s earnings last quarter?
MicroTech Medical (Hangzhou) Co., Ltd. Class H released its earnings results on Mar 30, 2026. The company reported HK$0.116 earnings per share for the quarter, the consensus estimate of HK$0.116 by HK$0.
Is MicroTech Medical (Hangzhou) Co., Ltd. Class H overvalued?
According to Wall Street analysts MicroTech Medical (Hangzhou) Co., Ltd. Class H’s price is currently Undervalued.
Does MicroTech Medical (Hangzhou) Co., Ltd. Class H pay dividends?
MicroTech Medical (Hangzhou) Co., Ltd. Class H does not currently pay dividends.
What is MicroTech Medical (Hangzhou) Co., Ltd. Class H’s EPS estimate?
MicroTech Medical (Hangzhou) Co., Ltd. Class H’s EPS estimate is 0.09.
How many shares outstanding does MicroTech Medical (Hangzhou) Co., Ltd. Class H have?
MicroTech Medical (Hangzhou) Co., Ltd. Class H has 169,175,840 shares outstanding.
What happened to MicroTech Medical (Hangzhou) Co., Ltd. Class H’s price movement after its last earnings report?
MicroTech Medical (Hangzhou) Co., Ltd. Class H reported an EPS of HK$0.116 in its last earnings report, expectations of HK$0.116. Following the earnings report the stock price went down -1.545%.
Which hedge fund is a major shareholder of MicroTech Medical (Hangzhou) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2235
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MicroTech Medical (Hangzhou) Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.72%
12-Months-Change
Fundamentals
Return on Equity
2.07%
Trailing 12-Months
Asset Growth
12.66%
Trailing 12-Months
Company Description
MicroTech Medical (Hangzhou) Co., Ltd. Class H
MicroTech Medical (Hangzhou) Co., Ltd. focuses on the innovation, production, and market distribution of essential medical devices and consumables for diabetes management. Its operations extend across the People's Republic of China and into global markets. The company offers a comprehensive range of products, including the Equil Patch insulin pump systems, AiDEX continuous glucose monitoring systems, POCT analyzer systems, traditional blood glucose monitoring systems, and advanced closed-loop artificial pancreas technology. Beyond its core offerings, MicroTech Medical is also actively involved in engineering and technological research, experimentation, and developmental endeavors. The firm, established in 2011, maintains its headquarters in Hangzhou, People's Republic of China.
2235 Stock 12 Month Forecast
Average Price Target
HK$11.63
▲(63.85% Upside)
Technical Analysis
MicroPort Scientific
―
Peijia Medical Ltd.
―
LifeTech Scientific Corporation
―
Vincent Medical Holdings Limited
―
MicroPort CardioFlow Medtech Corp.
―
Options Prices
Currently, No data available
---